HOME > TOP STORIES
TOP STORIES
-
BUSINESS Pfizer Japan Cedes Crown as Top Rep Holder as Global Players Continue to Seek Leaner Sales Force: Survey
May 9, 2018
-
BUSINESS Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
-
BUSINESS Takeda Cuts Deal to Acquire Shire in Japan’s Biggest Buyout
May 8, 2018
-
BUSINESS Over 60% of Drug Makers Cut New Grad Hires in FY2018, Otsuka Tops List Again: Tally
May 8, 2018
-
BUSINESS Competition Heating Up for HIF-PH Inhibitors; Astellas Expected to Be First with Filing Likely in FY2018
May 7, 2018
-
BUSINESS Japan to Join Jardiance Study for CKD under Collaboration between Boehringer, Lilly, and Oxford
May 2, 2018
-
BUSINESS Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
May 1, 2018
-
BUSINESS Bayer Japan Chief “Disappointed” at PMP Removal for Xarelto, Shows Eagerness for Add’l Indications
April 27, 2018
-
REGULATORY Imfinzi Sails through MHLW Panel, Now in Line for Stage III NSCLC Nod
April 26, 2018
-
ORGANIZATION PhRMA/EFPIA Say Humira, Jevtana, Xarelto Lost Eligibility under New PMP, Innovation Not Appropriately Defined
April 26, 2018
-
BUSINESS Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
-
BUSINESS Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
-
BUSINESS Novartis Seeks Japan Approval for Kymriah, Will Outcome-Based Model Be Put in Place?
April 24, 2018
-
ACADEMIA Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020
April 23, 2018
-
BUSINESS Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
-
BUSINESS Takeda in Talks with Shire after 3 Buyout Proposals Rejected
April 20, 2018
-
TRENDS Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers
April 20, 2018
-
BUSINESS Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
April 19, 2018
-
ACADEMIA Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
April 19, 2018
-
BUSINESS Another Huge Seller Re-Pricing Won’t Hit Opdivo Unless 195 Billion Yen Sales Reached: Ono Chief
April 18, 2018
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
